170 related articles for article (PubMed ID: 7969059)
41. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.
Dereuddre S; Delaporte C; Jacquemin-Sablon A
Cancer Res; 1997 Oct; 57(19):4301-8. PubMed ID: 9331091
[TBL] [Abstract][Full Text] [Related]
42. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
43. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast.
Wasserman RA; Austin CA; Fisher LM; Wang JC
Cancer Res; 1993 Aug; 53(15):3591-6. PubMed ID: 8393377
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
45. Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.
Sengupta T; Mukherjee M; Das A; Mandal C; Das R; Mukherjee T; Majumder HK
Biochem J; 2005 Sep; 390(Pt 2):419-26. PubMed ID: 15901238
[TBL] [Abstract][Full Text] [Related]
46. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
47. Type II topoisomerase mutations in clinical isolates of Enterobacter cloacae and other enterobacterial species harbouring the qnrA gene.
Lascols C; Robert J; Cattoir V; Bébéar C; Cavallo JD; Podglajen I; Ploy MC; Bonnet R; Soussy CJ; Cambau E
Int J Antimicrob Agents; 2007 Apr; 29(4):402-9. PubMed ID: 17254753
[TBL] [Abstract][Full Text] [Related]
48. The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
Boege F; Gieseler F; Biersack H; Meyer P
Eur J Clin Chem Clin Biochem; 1992 Feb; 30(2):63-8. PubMed ID: 1316175
[TBL] [Abstract][Full Text] [Related]
49. [Antitumor agents targeting mammalian topoisomerases].
Nakano H
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681
[TBL] [Abstract][Full Text] [Related]
50. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Oct; 92(10):1133-7. PubMed ID: 11676865
[TBL] [Abstract][Full Text] [Related]
51. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.
Gilroy KL; Leontiou C; Padget K; Lakey JH; Austin CA
Nucleic Acids Res; 2006; 34(5):1597-607. PubMed ID: 16549872
[TBL] [Abstract][Full Text] [Related]
52. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
van Hille B; Hill BT
Cancer Chemother Pharmacol; 1998; 42(5):345-56. PubMed ID: 9771947
[TBL] [Abstract][Full Text] [Related]
53. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
[TBL] [Abstract][Full Text] [Related]
54. Resistance mechanisms to topoisomerase poisons: the application of cell culture methods.
Baguley BC; Finlay GJ; Ching LM
Oncol Res; 1992; 4(7):267-74. PubMed ID: 1360275
[TBL] [Abstract][Full Text] [Related]
55. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast.
Meczes EL; Marsh KL; Fisher LM; Rogers MP; Austin CA
Cancer Chemother Pharmacol; 1997; 39(4):367-75. PubMed ID: 9025779
[TBL] [Abstract][Full Text] [Related]
56. Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme.
Wasserman RA; Wang JC
J Biol Chem; 1994 Aug; 269(33):20943-51. PubMed ID: 8063712
[TBL] [Abstract][Full Text] [Related]
57. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
58. Using yeast to study resistance to topoisomerase II-targeting drugs.
Nitiss JL
Cancer Chemother Pharmacol; 1994; 34 Suppl():S6-13. PubMed ID: 8070029
[TBL] [Abstract][Full Text] [Related]
59. Computational analysis of Amsacrine resistance in human topoisomerase II alpha mutants (R487K and E571K) using homology modeling, docking and all-atom molecular dynamics simulation in explicit solvent.
Sader S; Wu C
J Mol Graph Model; 2017 Mar; 72():209-219. PubMed ID: 28110185
[TBL] [Abstract][Full Text] [Related]
60. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
